|
|||||
|
|
Bortezomib and heart failure: case‐report and review of the French Pharmacovigilance database |
|
| Authors: | Benjamin Honton Fabien Despas Nicolas Dumonteil Caroline Rouvellat Murielle Roussel Didier Carrie Michel Galinier Jean Louis Montastruc Atul Pathak |
| Affiliation: | 1. Centre Hospitalier et Universitaire de Toulouse, Service de Cardiologie, , F‐31432 Toulouse, France;2. Institut National de la Santé et de la Recherche Médicale INSERM, Institut des Maladies Métaboliques et cardiovasculaires I2MC, Université de Toulouse, UPS, , F‐31432 Toulouse, France;3. Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de L'Université de Toulouse III Paul Sabatier, , F‐31432 Toulouse, France;4. Centre Midi‐Pyrénées de Pharmacovigilance, Service de Pharmacologie Clinique, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, , 31000 Toulouse, France;5. Service d'Hématologie, Centre Hospitalier et Universitaire de Toulouse, , F‐31432 Toulouse, France;6. Equipe de Pharmacoépidémiologie de l'UMR INSERM 1027, Faculté de Médecine de l'Université de Toulouse, , 31000 Toulouse, France |
| Abstract: | Bortezomib is a proteasome inhibitor commonly indicated for the treatment of multiple myeloma and non Hodgkin lymphoma. Cardiac adverse drug reactions of this drug are not clearly established. We report case where direct involvement of bortezomib in the occurrence of heart failure is strongly suspected and 22 other cases spontaneously reported to the French Pharmacovigilance System. This report should increase cardiologist awareness about the risk of heart failure related to this drug. Moreover, these cases underline the need for a systematic cardiac screening in patients exposed to bortezomib. |
| Keywords: | bortezomib heart failure pharmacovigilance |